Pieter Mestdagh is focused on studying the role of non-coding RNAs in cancer by combining wet lab and dry lab activities. He is co-founder of various international consortia related to the study of ncRNAs including the miRNA Quality Control consortium (miRQC), the extracellular vesicles Quality Control study (evQC), the extracellular RNA Quality Control study (exRNAQC) and the RNA-Atlas consortium. His work contributed to novel insights on the role of miRNAs and lncRNAs in various cancer types such as neuroblastoma and melanoma. Currently, his lab is evaluating the application of cancer-type specific (non-coding)RNAs as biomarkers in circulation and novel targets for therapy.
Pieter Mestdagh authored more than 100 articles in international peer reviewed journals and is an inventor on 6 patents. His work has been awarded with various national prices and he was nominated among the top 5 young investigators in Belgium and the Netherlands by The New Scientist. Pieter Mestdagh currently holds positions as an assistant professor at Ghent University and group leader at the Cancer Research Institute Ghent. His H-index is 58, with over 12,500 citations (Web of Science, September 2024).
PhD in Biomedical Sciences, 2011
Ghent University
Master of Bioscience Engineering, 2006
Ghent University
Master of Industrial Engineering, 2004
KAHO Sint-Lieven